Dr. Eric S. Daar, M.D.
Infectious Disease (Infectious Disease Physician)
21840 Normandie Ave, Ste. 700
Torrance, CA 90502
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Georgetown University School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
Licensed in California since 1986, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CA license G58472 (first issued 1986; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Lac/harbor-UCLA Med Center Torrance, CA
Medical groups
- County of Los Angeles (397 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Torrance, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 48 payments worth $20,708 in total to this clinician.
| Gilead Sciences, Inc. | $9,248 |
|---|---|
| Merck Sharp & Dohme LLC | $7,912 |
| Shionogi Inc | $3,300 |
| Viiv Healthcare Company | $138 |
| Paratek Pharmaceuticals, Inc. | $78.86 |
| Astellas Pharma US Inc | $31.72 |
| Consulting Fee | $15,010 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,182 |
| Travel and Lodging | $1,458 |
| Food and Beverage | $1,057 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Apr 15, 2025 | Consulting FeeCompany’s description;4074084;GTF;10024524 | $8,920 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $4,640 |
| Shionogi Inc Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) S-217622 · Infections and Infectious Diseases | $3,182 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $696 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $435 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $435 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $313 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $299 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $290 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $290 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $4,640 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Nov 18, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $299 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $696 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging PIFELTRO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $313 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $290 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $290 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $435 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $435 |
| Gilead Sciences, Inc. Apr 15, 2025 | Consulting FeeCompany’s description;4074084;GTF;10024524 | $8,920 |
| Shionogi Inc Feb 17, 2025 | Compensation for services other than consulting (speaking, faculty) S-217622 · Infections and Infectious Diseases | $3,182 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,603 in research payments for these studies, mostly to the institutions running them.
- A phase iiib, randomized, multicenter, parallel-group, non-inferiority
Viiv Healthcare Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.